| Multidimensional molecular profiling of metastatic triple-negative breast cancer and immune checkpoint inhibitor benefit R Barroso-Sousa, J Forman, K Collier, ZT Weber, TR Jammihal, KZ Kao, ... JCO Precision Oncology 6, e2100413, 2022 | 9 | 2022 |
| Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience. RM Saliby, T Jammihal, C Labaki, W Xie, RJ Motzer, T Powles, BI Rini, ... Journal of Clinical Oncology 40 (16_suppl), 4531-4531, 2022 | 4 | 2022 |
| Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes RM Saliby, C Labaki, TR Jammihal, W Xie, M Sun, V Shah, E Saad, ... Cancer cell, 2024 | 1 | 2024 |
| 1891P Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma RM Saliby, T Jammihal, C Labaki, H Soulati, J Gallegos, A Peris, ... Annals of Oncology 34, S1017, 2023 | 1 | 2023 |
| Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma S Shukla, T Jammihal, RM Saliby, C Labaki, H Soulati, J Gallegos, ... | | 2023 |
